'Slam dunk' for Astellas antifungal Cresemba at FDA panel
This article was originally published in PharmAsia News
Executive Summary
Astellas had few battles to wage on 22 January when it took its experimental antifungal Cresemba (isavuconazonium) before the U.S. FDA's Anti-Infective Drugs Advisory Committee (AIDAC), which wholeheartedly embraced the medicine as a treatment for the deadly invasive infection aspergillosis, and nearly so for use in another fungal infection, mucormycosis.